Hydroxychloroquine Monitoring Improves Lupus Outcomes
Publication Title: Real‐world Longitudinal Data on the Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes: Results of a Prospective Longitudinal Cohort Study
Summary
- Question
- This study examined how monitoring hydroxychloroquine (HCQ) blood levels impacts outcomes in systemic lupus erythematosus (SLE), focusing on whether maintaining therapeutic HCQ levels improves disease control and reduces flares.
- Why it Matters
- Hydroxychloroquine is a key treatment for SLE, a chronic autoimmune disease where the immune system attacks healthy tissues. Despite weight-based dosing, individual factors such as kidney function and drug metabolism can cause significant variations in HCQ levels, risking toxicity or inadequate treatment. Understanding how HCQ blood levels influence SLE outcomes can help optimize treatment and improve disease management, especially for patients with conditions like chronic kidney disease.
- Methods
- The researchers conducted a longitudinal study with 247 patients diagnosed with SLE over two years, analyzing data from 962 clinical visits. HCQ blood levels were measured alongside kidney function, disease activity, and adherence. Statistical models evaluated the relationship between HCQ levels and SLE activity, considering both individual and group-level variations over time.
- Key Findings
- Patients with very low (<200 ng/mL) or subtherapeutic HCQ levels (200–<750 ng/mL) had 6.7-fold and 2.6-fold higher odds of active SLE, respectively, compared to those with therapeutic levels (750–1,150 ng/mL). Maintaining therapeutic HCQ levels across all visits reduced the odds of active SLE by 83%. Patients with reduced kidney function (estimated glomerular filtration rate ≤75 mL/min/1.73m²) often had HCQ levels exceeding the therapeutic range, increasing toxicity risk despite weight-based dosing.
- Implications
- Routine monitoring of HCQ blood levels could improve disease control in SLE by enabling personalized dosing adjustments based on individual factors such as kidney function and adherence. This approach may reduce the risk of disease flares, toxicity, and hospitalizations, offering a more precise treatment strategy compared to standard weight-based dosing.
- Next Steps
- The researchers recommend further studies to evaluate the safety and effectiveness of HCQ blood level-guided dosing in diverse patient populations, particularly those with impaired kidney function. They also suggest exploring the integration of HCQ monitoring into routine clinical practice to optimize SLE management.
- Funding Information
- This research was supported by a grant from the Lupus Foundation of America, Wisconsin Chapter Research Award, and the Rheumatology Research Foundation Innovation Research Award. Assay services for this study were funded by the National Institutes of Health (NIH grant P51-OD-011106). Dr. Shivani Garg's work was supported by the NIH (grant 5K23-AR-084608-02). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Full Citation
Patel JJ, MPH FH, Packee C, Kapoor A, Rovin B, Costedoat‐Chalumeau N, Garg S. Real‐world Longitudinal Data on the Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes: Results of a Prospective Longitudinal Cohort Study. Arthritis Care & Research 2026, acr.80059. DOI: 10.1002/acr.80059.